You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 50 No. 12, December 1993 TABLE OF CONTENTS
  Archives
  •  Online Features
  Original Contributions
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Anti-Peripheral Nerve Myelin Antibodies and Terminal Activation Products of Complement in Serum of Patients With Acute Brachial Plexus Neuropathy

Francine J. Vriesendorp, MD; George S. Dmytrenko, MD, PhD; Terry Dietrich, MD; Carol L. Koski, MD

Arch Neurol. 1993;50(12):1301-1303.


Abstract

Objective
To determine if complement-fixing antibodies to peripheral nerve myelin (anti-PNM antibodies) and terminal complement activation products were increased in serum of patients with brachial plexus neuropathy compared with normal controls.

Design
Case series.

Setting
University medical center.

Patients
Three patients (aged 6, 39, and 51 years) with acute brachial plexus neuropathy were studied during the acute and recovery phase of their disease.

Methods
Anti-PNM antibodies were measured in serum samples obtained from three patients and 25 normal controls with the Cl fixation and transfer assay. Soluble terminal complement activation products, SC5b-9, were measured by enzyme-linked immunosorbent assay (ELISA) in serum samples of one patient with brachial plexus neuropathy and of five normal controls.

Results
Both serum anti-PNM antibodies and soluble terminal complement activation products were increased in the acute phase of brachial plexus neuropathy compared with normal control values and decreased several months later during clinical recovery.

Conclusion
Complement dependent, antibodymediated demyelination may participate in the peripheral nerve damage of brachial plexus neuropathy.



Author Affiliations

From the Department of Neurology, University of Maryland Hospital and School of Medicine, Baltimore. Dr Vriesendorp is now with the Department of Neurology, University of Texas Health Science Center, Houston.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Neuralgic amyotrophy
Sathasivam et al.
J Bone Joint Surg Br 2008;90-B:550-553.
ABSTRACT | FULL TEXT  

Motor root conduction in neuralgic amyotrophy: evidence of proximal conduction block
Lo and Mills
J. Neurol. Neurosurg. Psychiatry 1999;66:586-590.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1993 American Medical Association. All Rights Reserved.